Mumbai, Baltimore, July03, 2023: Global pharma major Lupin Limited today announced that it has received approval from the United States Food and Drug Administration for its.
Mumbai, Baltimore, June 23, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel® Oral Suspension, 40 mg/mL of Eisai Inc. .
Mumbai, Baltimore, June21, 2023: Global pharma major Lupin Limited today announced that it has received approval from the United States Food and Drug Administration for its. | June 21, 2023
Mumbai, Baltimore, June21, 2023: Global pharma major Lupin Limited today announced that it has received approval from the United States Food and Drug Administration for its. | June 21, 2023